BridgeBio Pharma (NASDAQ:BBIO) Downgraded by Zacks Investment Research to “Sell”

Retrieved on: 2019-11-21 23:56:15

Tags for this article:

Click the tags to see associated articles and topics

BridgeBio Pharma (NASDAQ:BBIO) Downgraded by Zacks Investment Research to “Sell”. View article details on HISWAI:

Excerpt

<div><b>Kohlberg Kravis Roberts</b> & Co. L.P. bought a new stake in shares of BridgeBio Pharma in the 2nd quarter worth approximately $995,211,000.</div>

Article found on:

View Original Article